Navigation Links
Plexus Systems, Inc. to Exhibit at BIOMEDevice Medical Technology Conference
Date:9/5/2008

Plexus Online highlighted during industry-leading event September 10 - 11,

2008 San Jose, California

AUBURN HILLS, Mich., Sept. 5 /PRNewswire/ -- Plexus Systems, Inc., provider of Plexus Online on-demand software for the medical manufacturing enterprise, is exhibiting at the BIOMEDevice Medical Technology Conference September 10-11, 2008 at the San Jose McEnery Conference Center, San Jose, California.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070627/CLW071LOGO )

The event convenes over 5,000 professionals from biotechnology, medical device, and pharmaceutical organizations across the globe. BIOMEDevice showcases the latest advances in medical device manufacturing, automation/robotics, medical device software and validation solutions, enterprise-wide IT, and a full range of contract service providers.

"This is a great venue to showcase how Plexus Online on demand ERP changes the way medical device manufacturers operate and succeed," said Plexus Systems vice president of marketing Patrick Fetterman. "The software as a service enables full-featured traceability, quality management, supplier visibility, and production tracking to support rigorous regulatory requirements faced by the life sciences industry."

Plexus Online offers over 350 functional modules, providing medical manufacturers instant access to vital information and management functions using a simple Web browser. The on-demand solution Plexus Online handles documentation, audit support and data security to be compliant with TS13485 and ISO 9001 mandates; CFR and FDA compliance; audits; and corrective Action/Preventive Action (CAPA) and Process/Product PQ functionality. The system features quality management and problem resolution management, enterprise resource planning (ERP) functions such as accounting and finance modules, manufacturing execution systems (
'/>"/>

SOURCE Plexus Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Plexus Q2 Earnings Release on April 23rd After Market Close and Conference Call on April 24th at 8:30 am E.T.
2. Plexus Q2 Earnings Release on April 23rd After Market Close and Conference Call on April 24th at 8:30 am E.T.
3. Plexus Announces Expansion in Hangzhou, China
4. Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market
5. Mark Whitacre, Ph.D. Promoted at Cypress Systems, Inc. and a Warner Brothers Movie to Be Filmed About Him
6. Cypress Systems, Inc. Launches Cancer Prevention Health Campaign Using SelenoExcell(R)
7. Solei Systems, Inc., Announces That the Company Is Now Publicly Traded
8. StemCor Systems, Inc. Awarded NIH SBIR Grant for Bone Marrow Aspiration Platform
9. Concuity Announces Partnership with Financial Healthcare Systems, LLC
10. CEOs Letter to Shareholders of Imaging Diagnostic Systems, Inc.
11. Avantis Medical Systems, Inc. Announces Key Leadership Appointments

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Biotech..."Company") today announced updated results from a ...nts with sarcomas metastatic to the lung in a post...ue Oncology Society Meeting held in Miami Beach, F...ntation, entitled "A Phase II Study of Intravenous...
(Date:11/6/2009)... The agenda for Arrowhead’s 2010 P...h is set to take place on February 22-24, 2010 in ...y conference we will highlight key issues in formi...are their experiences. , ...enda for Arrowhead’s 2010 Personalized Medi...
(Date:11/5/2009)...URG, Md., Nov. 5 GenVec,...al results for the third quarter ended September 3...n ($0.04 per share) for the three months ended Sep...lion ($0.08 per share) in the comparable quarter o...09, GenVec,s net loss was $14.1 million ($0.15 per...
(Date:11/5/2009)...Y, N.J., Nov. 5 DSM Pharmaceutical...acturing alliance with Galenix, Saint Jean D,Illac...al scale manufacturing partner for Galenix commerc...nix will collaborate on business development oppor...logies, based on the strength of Galenix in drug p...
Breaking Biology Technology:Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3
...UT CREEK, CAGenomics is accelerating improvements ...ernative to fossil fuel for the nation,s transport....S. Department of Energy Joint Genome Institute (D...Nature . In "Genomics of cellulosic biofuels," Ru...ic technologies will contribute to a substantially...
...SON Electronic devices get smaller and more compl...price for miniaturization, especially when it come...he floor. Wouldn,t it be great if they bounced ins... University researchers, led by Apparao Rao, profe...f tiny, shock-absorbing carbon springs which possi...
...ON, Mass., Aug. 13 Indevus,Pharmaceuticals, Inc. ....S.,Patent No. 7,410,978 (the ",978 patent"), enti...is licensed exclusively to the Company by the pate...e ,978 patent covers the Company,s approved produc...spium chloride which is indicated for the,treatmen...
Other Biology Technology:DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature 2DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature 3DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature 4Clemson scientists put a (nano) spring in their step 2Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM) 2Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM) 3
(Date:11/4/2009)...4 GenVault Corporation (Carlsbad, ...., has joined its Board of Directors. Dr. Brody, ...stitute, is an acclaimed physician-scientist and u...tute, Dr. Brody served as president of The Johns H... Academy of Engineering and the Institute of Medic...
(Date:11/3/2009)...ultimate loner of the ocean, cruising thousands of...rs has discovered that the sharks have maintained ...ens of thousands of years the white sharks in the ...es into a population genetically distinct from sha...a large, highly mobile species," said Salvador Jor...
(Date:11/3/2009)...Ind. - Chief executives in 35 of the top Fortune 5...r "ideal salaries" in 2008, according to a new typ...versity researcher to determine fair CEO compensat...rporate governance issues of the day is how to det...nkatasubramanian, a professor of chemical engineer...
Breaking Biology News(10 mins):Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 2Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 3Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers 2Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers 3Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers 4New theory on fairness in economics targets CEO pay 2New theory on fairness in economics targets CEO pay 3New theory on fairness in economics targets CEO pay 4Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 1Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 2Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 3Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 4Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 5Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 6Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 7NeurogesX Reports Second Quarter 2009 Results 13446 1NeurogesX Reports Second Quarter 2009 Results 13446 2NeurogesX Reports Second Quarter 2009 Results 13446 3NeurogesX Reports Second Quarter 2009 Results 13446 4NeurogesX Reports Second Quarter 2009 Results 13446 5NeurogesX Reports Second Quarter 2009 Results 13446 6NeurogesX Reports Second Quarter 2009 Results 13446 7NeurogesX Reports Second Quarter 2009 Results 13446 8NeurogesX Reports Second Quarter 2009 Results 13446 9NeurogesX Reports Second Quarter 2009 Results 13446 10NeurogesX Reports Second Quarter 2009 Results 13446 11NeurogesX Reports Second Quarter 2009 Results 13446 12Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 1Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 2Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 3Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 4Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 5Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 6Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 7Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 8Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 9Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 10Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 11Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 12Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 13Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 14Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 15Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 16Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 17Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 18
... Cancer Research at the University of California, ...rkable property of the contractile ring, a structu...the contractile ring works to divide the cell may ...ontrolled cell division in cancer. , The researc...he length of the contractile ring are reduced duri...
...iety (ACerS) announced today that it is launching ...edicated to glass research: The International Jou...enerations of glass and glass-related materials ar... many of the world,s emerging technologies, includ... environmental, optical and defense technologies s...
.... , In the context of the climatic change of th... global warming are of great interest. That is the...pension of solid or liquid particles on a gaseous ...cooling of the atmosphere. , Juan Luis Guerrero ...nique for atmospheric characterization by elastic ...
Other Biology News:Study may aid efforts to prevent uncontrolled cell division in cancer 2New journal on advanced glass research to debut 2A research work will be the reference to characterize the climatic impact of desert dust 2
GIBCO Streptomycin Sulfate from Invitrogen
GIBCO Dulbeccos Modified Eagle Medium (D-MEM) (1X); powder (low glucose) from Invitrogen
Goat Anti-Adducin beta (C-16) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Rat TNF-alpha ELISA Kit, OptEIA from BD Biosciences Pharmingen
Biology Products: